In July 15, the U. S. Food and Drug (FDA) Administration approved IRESSA (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types…
Everything about lung cancer is here.
In July 15, the U. S. Food and Drug (FDA) Administration approved IRESSA (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types…